Rep. Waxman: DTC ban a priority

Share this article:
Rep. Henry Waxman
Rep. Henry Waxman
Giving FDA the power to impose two-year moratoria on consumer ads for some new drugs will be a priority for Rep. Henry Waxman as he takes the reins of the Committee on Energy and Commerce.

Waxman (D-CA) told attendees at a Prescription Project conference in Washington yesterday that he would support legislation allowing the agency to ban ads for new drugs on a case-by-case basis for up to two years after approval.

“It is in these first few years of a drug's life that drug companies often aggressively market their products and engage in direct-to-consumer advertising,” Reuters quoted Waxman as saying. “This increases the number of consumer exposed to safety risks of new products long before those risks are truly understood.”

Waxman said Congress also needs to do something about physician marketing, because the “most persuasive, effective advertising” goes on in the doctor's office. He cited off-label marketing and selective use of clinical information, the Prescription Project's blog reported, and said he supports Sen. Herb Kohl's academic detailing bill, the Independent Drug Education and Outreach Act. He said he had not had a chance to review the Physician Payments Sunshine Act.

Waxman is set to take over the powerful committee, which has primary oversight on health policy and spending, having ousted longtime chairman (and fellow DTC critic) John Dingell (D-MI) last month. He previously headed the Committee on Oversight and Government Reform, a perch from which he launched inquiries into drug safety, pricing and marketing practices.  
Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?